Drugs / Tepilamide Fumarate
Tepilamide Fumarate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03421197 | Jan 2018 → Mar 2020 | psoriasis | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 2 | NCT02173301 | Jun 2014 → May 2015 | psoriasis | Dr. Reddy's Laboratories Limited | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tepilamide Fumarate | “PPC-06 (Tepilamide Fumarate)” NCT03421197 ↗ |
| Known as | Fumarate de tepilamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989961 ↗ |
| Known as | Fumarato de tepilamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989961 ↗ |
| Known as | PPC-06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03421197 ↗ |
| Known as | XP23829 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02173301 ↗ |
| Modality | Small molecule | — CHEMBL3989961 ↗ |